Karen Rodriguez Lorenc

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · Journal of Clinical Oncology · 2018 · 1.1K citations

Medicine, Oncology, Pharmacology +14

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Naresh Bumma, Joshua Richter, Sundar Jagannath et al. · Journal of Clinical Oncology · 2024 · 135 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer

Howard A. Burris, Arlene Chan, Aditya Bardia et al. · British Journal of Cancer · 2021 · 90 citations · Full text

Medicine, Oncology, Pharmacology +14

Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib

Aditya Bardia, Fei Su, Nadia Solovieff et al. · JCO Precision Oncology · 2021 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Naresh Bumma, Joshua Richter, Jason Brayer et al. · Blood · 2022 · 40 citations

Medicine, Hematology, Oncology +17